title: Paris Saponin I Sensitizes Gastric Cancer Cell Lines to Cisplatin via Cell Cycle Arrest and Apoptosis.
abstract: BACKGROUND Dose-related toxicity is the major restriction of cisplatin and cisplatin-combination chemotherapy, and is a challenge for advanced gastric cancer treatment. We explored the possibility of using Paris saponin I as an agent to sensitize gastric cancer cells to cisplatin, and examined the underlying mechanism. MATERIAL AND METHODS Growth inhibition was detected by MTT assay. The cell cycle and apoptosis were detected using flow cytometry and Annexin V/PI staining. The P21waf1/cip1, Bcl-2, Bax, and caspase-3 protein expression were detected using Western blot analysis. RESULTS The results revealed that PSI sensitized gastric cancer cells to cisplatin, with low toxicity. The IC50 value of cisplatin in SGC-7901 cell lines was decreased when combined with PSI. PSI promoted cisplatin-induced G2/M phase arrest and apoptosis in a cisplatin concentration-dependent manner. Bcl-2 protein expression decreased, but Bax, caspase-3, and P21waf1/cip1 protein expression increased with PSI treatment. CONCLUSIONS The underlying mechanism of Paris saponin I may be related to targeting the apoptosis pathway and cell cycle blocking, which suggests that PSI is a potential therapeutic sensitizer for cisplatin in treating gastric cancer.
authors.affiliation: Department of Gastroenterology, 117 Hospital of People's Liberation Army, Hangzhou, Zhejiang, China (mainland).
authors.forename: Shuichuan
authors.initials: S
authors.lastname: Song
authors.affiliation: Department of Gastroenterology, 117 Hospital of People's Liberation Army, Hangzhou, Zhejiang, China (mainland).
authors.forename: Leiwen
authors.initials: L
authors.lastname: Du
authors.affiliation: Department of Oncology, Zhejiang Hospital, Hangzhou, Zhejiang, China (mainland).
authors.forename: Hao
authors.initials: H
authors.lastname: Jiang
authors.affiliation: Department of Thoracic Surgery, Zhejiang Hospital, Hangzhou, Zhejiang, China (mainland).
authors.forename: Xinhai
authors.initials: X
authors.lastname: Zhu
authors.affiliation: Department of Chinese Medicine and Rehabilitation, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China (mainland).
authors.forename: Jinhui
authors.initials: J
authors.lastname: Li
authors.affiliation: Department of Surgery, Huashan Luxeme Medical Cosmetology Hospital, Hangzhou, Zhejiang, China (mainland).
authors.forename: Ji
authors.initials: J
authors.lastname: Xu
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D053148:Caspase 3 / Q000378:metabolism; D002453:Cell Cycle / Q000187:drug effects; D059447:Cell Cycle Checkpoints / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology*; D004144:Diosgenin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D004357:Drug Synergism; D006801:Humans; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D012503:Saponins / Q000008:administration & dosage / Q000494:pharmacology*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D051028:bcl-2-Associated X Protein / Q000378:metabolism
chemical_list: D019253:Proto-Oncogene Proteins c-bcl-2; D012503:Saponins; D051028:bcl-2-Associated X Protein; C121203:polyphyllin D; D053148:Caspase 3; D004144:Diosgenin; D002945:Cisplatin